Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ZP9830 in Healthy Participants
NCT06682975Phase 1Recruiting
- Sponsor
- Zealand Pharma
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing ZP9830 Arm with Placebo Arm (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 41 days. Started Nov 2024; status: recruiting.
02
Drugs
ZP9830
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06682975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682975.